Premium Industrial News

Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal

Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal

Lonza Building New Swiss Plant, Expands Moderna COVID-19 Manufacturing Deal

Author: Martin Lynch | Published: April 30, 2021
Industry Segment: Pharmaceutical & Biotech  |  Word Count: 1127 Words

GALWAY, IRELAND--May 5, 2021--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss contract development and manufacturing organization (CDMO) Lonza Group (Basel, Switzerland) has announced a series of major projects for its Visp facility in Switzerland, including a new $218 million small molecule manufacturing complex and separate plans to double the drug substance production for Moderna's (NASDAQ:MRNA) (Cambridge, Massachusetts) COVID-19 vaccine.

Within this article: Details new small molecule plant investment, long-term COVID-19 deal with Moderna and related news

This Premium Article can be purchased individually or as part of a subscription

Subscribe Now!(All Fields Required)

Subscription Type:

  • Pay-Per-Article - $5.95
  • Annual Premium News Subscription - $365.00
Pricing Help?